• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections
 


New Search Back to Search Results
 
Trade NameTHERASCREEN KRAS RGQ PCR KIT
Classification Namesomatic gene mutation detection system
ApplicantQIAGEN MANCHESTER LTD
PMA NumberP110030
Date Received07/28/2011
Decision Date07/06/2012
Product Code
OWD[ Registered Establishments with OWD ]
Docket Number 12M-0735
Notice Date 07/16/2012
Advisory Committee Pathology
Clinical Trials NCT00079066
Expedited Review Granted? No
Combination Product Yes
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Approval Order Statement 
Approval for the therascreen kras rgq pcr kit. This device is indicated for: the therascreen kras rgq pcr kit is a real-time qualitative pcr assay used on the rotorgene q mdx instrument for the detection of seven somatic mutations in the human kras oncogene, using dna extracted from formalin fixed paraffin-embedded (ffpe), colorectal cancer (crc) tissue. The therascreen kras rgq pcr kit is intended to aid in the identification of crc patients for treatment with erbitux (cetuximab) based on a kras no mutation detected test result.
Approval Order Approval Order
-
-